pandem
caus
novel
coronaviru
call
affect
one
million
peopl
around
world
acronym
deriv
coronaviru
diseas
first
report
decemb
provinc
hubei
china
dissemin
part
countri
becom
global
threat
brazil
well
clinic
spectrum
vari
asymptomat
high
percentag
infect
peopl
sever
acut
respiratori
syndrom
sar
main
caus
death
specif
treatment
found
complet
effect
viru
vaccin
avail
yet
prevent
infect
therefor
therapeut
option
potenti
lethal
infect
must
discuss
ethic
scientif
histor
convalesc
plasma
cp
passiv
immunotherapi
use
possibl
therapeut
option
proven
specif
vaccin
drug
avail
emerg
infect
administr
convalesc
plasma
immunoglobulin
shown
shorten
hospit
stay
reduc
mortal
rate
patient
sar
respond
methylprednisolon
uncontrol
nonrandom
clinic
trial
cheng
et
al
investig
sar
patient
found
patient
transfus
sar
convalesc
plasma
lower
mortal
rate
compar
nontransfus
patient
vs
hung
colleagu
conduct
prospect
cohort
studi
offer
treatment
convalesc
plasma
antibodi
titer
infect
patient
intens
care
found
rel
risk
mortal
infect
significantli
reduc
patient
transfus
convalesc
correspond
author
plasma
compar
control
group
patient
declin
plasma
treatment
vs
p
addit
viral
load
level
interleukin
interleukin
tumor
necrosi
factor
decreas
significantli
subgroup
infect
patient
group
investig
conduct
multicent
prospect
doubleblind
random
control
clinic
trial
use
convalesc
plasma
fraction
hyperimmun
iv
immunoglobulin
hivig
comparison
normal
iv
manufactur
immunoglobulin
treat
sever
infect
patient
standard
antivir
treatment
requir
intens
care
ventilatori
support
result
show
infus
hivig
associ
lower
viral
load
reduc
mortal
within
day
symptom
onset
recommend
use
ebola
convalesc
plasma
transfus
empir
treatment
ebolainfect
peopl
outbreak
diseas
systemat
review
exploratori
metaanalysi
studi
assess
overal
evid
clinic
benefit
administr
convalesc
plasma
serum
hyperimmun
immunoglobulin
treatment
sever
acut
respiratori
infect
author
found
mortal
rate
significantli
reduc
follow
infus
seriou
advers
effect
anoth
metaanalysi
evalu
studi
includ
patient
spanish
influenza
pneumonia
found
absolut
reduct
casefat
among
patient
transfus
blood
product
deriv
influenza
convalesc
individu
past
week
investig
report
potenti
use
convalesc
plasma
transfus
adjunct
altern
therapi
sever
hospit
patient
shen
colleagu
describ
use
plasma
therapi
male
infect
patient
base
critic
condit
includ
sever
pneumonia
adult
respiratori
distress
syndrom
ard
mechan
ventil
support
rapid
diseas
progress
high
viral
load
patient
year
age
alreadi
treat
sever
antivir
drug
plu
methylprednisolon
receiv
convalesc
plasma
transfus
day
hospit
admiss
abo
compat
plasma
unit
collect
apheresi
year
asymptomat
patient
recov
infect
transfus
convalesc
plasma
contain
igg
antibodi
bind
titer
greater
evalu
enzymelink
immunosorb
assay
elisa
neutral
titer
greater
donor
test
neg
respiratori
virus
syphili
hiv
hepat
b
c
viru
time
plasma
donat
ml
convalesc
plasma
administ
day
apheresi
collect
patient
evalu
convalesc
plasma
transfus
chang
bodi
temperatur
sequenti
organ
failur
assess
sofa
ard
ventilatori
extracorpor
membran
oxygen
ecmo
viral
load
serum
antibodi
titer
blood
biochem
valu
author
observ
plasma
transfus
patient
bodi
temperatur
normal
within
day
increas
within
day
patient
ard
resolv
within
day
viral
load
also
neg
day
igg
neutral
antibodi
titer
increas
day
importantli
patient
discharg
hospit
day
stay
patient
stabl
clinic
statu
day
convalesc
plasma
transfus
author
conclud
data
show
potenti
benefit
convalesc
plasma
transfus
critic
ill
patient
howev
small
number
patient
absenc
control
group
preclud
definit
statement
potenti
effect
therapi
provid
evid
evalu
random
clinic
trial
analog
sar
infect
progress
intens
inflammatori
respons
eventu
caus
seriou
lung
damag
increas
mortal
risk
absenc
definit
cur
manag
mani
treatment
algorithm
explor
treatment
among
possibl
intervent
use
plasma
collect
recov
patient
show
initi
promis
howev
publish
result
rigor
clinic
trial
need
may
draw
definit
effect
conclus
passiv
antibodi
therapi
administr
convalesc
plasma
must
howev
fulfil
requir
relat
avail
recov
donor
welldesign
studi
protocol
guarante
efficaci
analysi
intervent
government
institut
complianc
laboratori
support
perform
serolog
molecular
assay
includ
measur
viral
neutral
immun
respons
addit
connect
hospit
blood
center
plasma
industri
must
follow
flawless
strategi
plasma
unit
may
frozen
distribut
manufactur
concentr
immunoglobulin
recent
us
food
drug
administr
unit
state
approv
use
plasma
recov
patient
treat
serious
ill
individu
transfus
plasma
must
obtain
donor
test
neg
plasma
collect
perform
day
clinic
recoveri
must
collect
recov
patient
without
symptom
least
day
worldwid
current
hundr
thousand
patient
recov
could
recruit
becom
convalesc
plasma
donor
cautiou
clinic
laboratori
evalu
igg
antibodi
passiv
transfer
transfus
plasma
might
neutral
viral
particl
activ
complement
system
thu
promot
viral
elimin
howev
also
import
recogn
plasma
transfus
may
associ
transfus
reaction
allerg
reaction
transfusionrel
acut
lung
injuri
trali
circulatori
overload
